Tesamorelin Oral Spray

Tesamorelin — oral format

15mL Oral Spray

This listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.

Because this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized Tesamorelin vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.

Technical overview

Growth hormone-releasing hormone (GHRH) analog

Tesamorelin is a stabilized analog of growth hormone-releasing hormone that stimulates pituitary GH secretion, raising IGF-1 and influencing body composition. It is distinctive among research-discussed peptides because a specific formulation received FDA approval to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

Phase 3 programs led by Falutz and colleagues demonstrated meaningful reductions in visceral adipose tissue over 26 weeks with daily subcutaneous administration, with extension data informing durability and metabolic secondary endpoints. Separate work evaluated liver fat and other cardiometabolic markers in HIV populations with central fat accumulation. These papers are the correct primary anchors for dosage education.

Outside labeled use, tesamorelin appears in broader body-composition research conversations. Educational content should keep approved indication, trial doses, and off-label speculation clearly separated, and should use research-use-only language for non-labeled contexts. This page summarizes documented ranges for reference by research professionals.

Mechanism of action

Tesamorelin binds pituitary GHRH receptors, amplifying physiologic GH pulsatility rather than supplying exogenous growth hormone directly. Increased GH acts on hepatic and peripheral tissues to raise IGF-1, promote lipolysis in visceral fat depots, and support lean-mass signals. Preferential VAT reduction with relative subcutaneous fat sparing was a recurring theme in HIV lipodystrophy trials. Downstream metabolic effects on triglycerides and hepatic fat have been examined as secondary physiology.

Research applications

• HIV-associated lipodystrophy
• visceral adiposity
• GH/IGF-1 axis
• hepatic fat in endocrine research
• body composition

Fields of active investigation, not claims. Investigation is not proof.

Infectious-disease and endocrinology investigators working on HIV metabolic complications are the core clinical-research audience. Body-composition and NAFLD-oriented teams analyze VAT and liver-fat imaging endpoints. Peptide educators reference tesamorelin as a fully specified GHRH-analog case study with published phase 3 dose regimens.

Amounts reported in the literature

What published research and laboratory protocols document. These describe what was studied — they are not instructions, recommendations, or a protocol for use.

Handling and storage

Approved product labeling specifies controlled storage and reconstitution steps; research lyophilizates should remain refrigerated per COA. Use diluent only as directed, refrigerate reconstituted solution, and discard after the labeled period.

Notes on combined research

Clinical trials evaluate tesamorelin on optimized antiretroviral and lifestyle backgrounds, not stacked with other GH secretagogues. Combining GHRH analogs with GHRPs/ghrelin mimetics is sometimes hypothesized to amplify GH release but introduces confounding and safety-monitoring complexity. Research designs usually isolate the GHRH analog.

Analytical specifications

Identity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.

Frequently asked questions

What is the dosage for tesamorelin?
Pivotal HIV-associated lipodystrophy trials used 2 mg subcutaneously once daily for the original formulation. That is the best-documented human dose anchor in the peer-reviewed literature. Newer branded presentations may list different nominal milligram strengths that are designed to be exposure-matched—always read the specific label or trial protocol.

How much bac water for tesamorelin?
Follow the product's reconstitution instructions when using approved kits. For research lyophilized vials, choose a diluent volume that delivers 2 mg in a convenient syringe volume (for example, 2 mg in 1 mL yields 2 mg/mL). Do not assume multi-peptide blend volumes apply.

Tesamorelin dosage per day
Daily dosing—not weekly—is the regimen used in the major VAT-reduction trials. Educational charts should show mcg or mg per day and note morning abdominal subcutaneous administration patterns described in clinical materials.

Tesamorelin dosage chart
A simple chart maps 2 mg daily to syringe units at your concentration. If reconstituted to 2 mg/mL, 1.0 mL = 2 mg. IGF-1 monitoring schedules from clinical practice are separate from the injection-volume chart and belong in protocol documents.

How long does tesamorelin take?
Primary VAT imaging endpoints in phase 3 work were assessed at 26 weeks, with extension observations to 52 weeks in some analyses. Benefits on visceral fat were treatment-dependent in follow-up discussions. Timelines refer to trial populations with HIV-associated central fat accumulation.

What is the half life of tesamorelin?
As a peptide GHRH analog, plasma persistence is short; pharmacodynamic effects run through GH secretion and IGF-1 elevation lasting longer than the parent peptide's plasma spike. Cite clinical pharmacology references for numeric half-life values.

Can tesamorelin be stacked with other peptides?
Evidence-based protocols study it as a single GH-axis agent. Stacking with CJC-1295, ipamorelin, or exogenous GH overlaps pathways and is not how pivotal trials were run. Research clarity favors monotherapy plus defined background care.

References

Every reference below resolves to an indexed paper. We would rather cite less and cite accurately.

• Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
• Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
• Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

Research use only

For laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications. This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.